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were calculated from the German CERAD-NAB normative 
sample (N = 1,081) using six different cut-off scores (i.e., 
1st, 2.5th, 7th, 10th, 16th, and 25th percentile). Results 
indicate that high percentages of one or more “abnormal” 
scores were obtained, irrespective of the cut-off criterion. 
For example, 60.6 % of the normative sample obtained one 
or more scores at or below the 10th percentile. These find-
ings illustrate the importance of considering the prevalence 
of low scores in healthy individuals. The summary figure 
of CERAD-NAB base rates is an important supplement for 
test interpretation and can be used to improve the diagnos-
tic accuracy of neurocognitive disorders.
Keywords Neuropsychology · Normal aging · 
Diagnosis · Neurocognitive disorders · Dementia ·  
Mild cognitive impairment
Abstract It is common for some healthy older adults 
to obtain low test scores when a battery of neuropsycho-
logical tests is administered, which increases the risk of 
the clinician misdiagnosing cognitive impairment. Thus, 
base rates of healthy individuals’ low scores are required 
to more accurately interpret neuropsychological results. At 
present, this information is not available for the German 
version of the Consortium to Establish a Registry for Alz-
heimer’s Disease-Neuropsychological Assessment Battery 
(CERAD-NAB), a frequently used battery in the USA and 
in German-speaking Europe. This study aimed to determine 
the base rates of low scores for the CERAD-NAB and to 
tabulate a summary figure of cut-off scores and numbers of 
low scores to aid in clinical decision making. The base rates 
of low scores on the ten German CERAD-NAB subscores 
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Introduction
When administered a battery of neuropsychological tests, 
some healthy older adults obtain low scores (e.g., [1–6]). 
Low test scores, especially low memory scores, obtained by 
healthy older adults might be interpreted as an indication of 
cognitive deterioration and lead to a false-positive diagno-
sis of mild cognitive impairment (MCI). Thus, to evaluate 
test results accurately and safeguard against misinterpreta-
tion of abnormal test performance, knowledge about base 
rates of low scores in healthy older adults compared to true 
pathological performance is of critical importance.
Cognitive deficits, particularly in episodic memory, rep-
resent a hallmark of Alzheimer’s disease (AD) dementia 
and are known to be detectable in prodromal stages, such 
as MCI [7–9]. However, given that healthy older adults 
may also show a gradual but clinically insignificant cog-
nitive decline over time [10, 11], these cognitive changes 
may be very subtle, such that in clinical practice detecting 
true cognitive impairment remains challenging [8]. Thus, to 
obtain an accurate understanding of an individual’s cogni-
tive functioning for a reliable and valid diagnosis, it is very 
important to differentiate normal changes with cognitive 
aging from cognitive changes that go beyond normal aging.
At present, however, no universally accepted and empir-
ically validated psychometric criteria exist to define cogni-
tive impairment [12, 13]. Cognitive deterioration is broadly 
defined in clinical practice, and different cut-off scores are 
used to define impairment. Thus, when assessing cognitive 
impairment, some methodological issues have to be con-
sidered. When administering only one neuropsychological 
test, the number of individuals being within the lower tail 
of the Gaussian distribution will depend on the chosen cut-
off score (e.g., when using the 7th percentile as the criti-
cal cut-off score, by definition, 7 % of cognitively healthy 
individuals would be erroneously classified as impaired). 
However, clinicians usually do not rely on a single test 
score, but on the patients’ performance on multiple tests 
when assessing cognition. The prevalence of low scores 
will then be considerably higher when the number of tests 
administered increases, compared to single test interpreta-
tion [1, 12]. Additionally, tests in a neuropsychological bat-
tery commonly show substantial intercorrelations and are 
therefore not independent, such that a non-consideration 
of this fact results in inaccurate assumptions (i.e., over- or 
underestimation) of neuropsychological test results. Thus, 
the number of tests in a test battery and the cut-off criterion 
applied affect the number of low scores: that is, as more 
tests are administered and less stringent [e.g., 25th per-
centile (z = −0.67)] cut-off scores are applied, then more 
“abnormal” scores will be obtained by healthy individuals 
[12, 14, 15]. Although the recommended criterion for low 
performance associated with MCI is 1.5 standard deviations 
(SD) below the mean of adjusted normative data [16], other 
cut-off scores ranging from 1.0 to 2.0 SD below the mean 
have been proposed by the National Institute on Aging and 
the Alzheimer’s Association [17] or the fifth edition of the 
American Psychiatric Association’s Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-5; [18]). However, 
the applied cut-off score needs to be considered carefully 
because the cut-off score selected substantially affects 
the rate of false-positive low scores [12, 19]. In addition, 
beside such psychometrical arguments, personal or situ-
ational factors may affect the prevalence of low scores (see 
[20]). For example, some people will be located at the low-
est (and highest) tail of the Gaussian distribution, i.e., these 
individuals have always performed low in the past and will 
also show weak performances in the future, although they 
are healthy. Longstanding weaknesses in certain cognitive 
areas may also account for low scores as well as situational 
factors such as the personal (daily) condition (poor sleep 
quality, fatigue, low motivation, attentional distraction, dis-
comfort during testing or tension, suffering from pain, bad 
emotional status, difficulties to adapt to test situation, etc.). 
Another source might consist of measurement errors such 
as misunderstandings of test instructions.
The presence of low scores in healthy older adults is a 
well-known phenomenon and a relevant issue for clinicians 
and researchers to consider, especially in order to safeguard 
against misinterpretation of some “abnormal” scores. How-
ever, this concept still remains relatively poorly understood 
and has certainly not yet been implemented in its full sig-
nificance in everyday clinical practice. Low scores are a 
common feature in any battery of tests and have already 
been reported by several research groups for different neu-
ropsychological tests or test batteries (e.g., [2]). However, 
at present this information is not available for the German 
version of the Consortium to Establish a Registry for Alz-
heimer’s Disease-Neuropsychological Assessment Battery 
(CERAD-NAB), a well-established and very commonly 
used battery in German-speaking Europe and the USA to 
assess mature individuals with potential neurocognitive dis-
orders [21, 22]. The CERAD-NAB yields ten standardized 
z-scores and is useful in discriminating between healthy 
older adults and patients with incipient AD or AD dementia 
[21, 23, 24]. Incorporating the base rates of low scores into 
clinical practice might reduce false-positive diagnoses that 
may cause anxiety and distress in both the affected indi-
viduals and their families, as well as reduce false-negative 
diagnoses that would prevent patients from receiving and 
profiting from early therapeutic interventions.
The objective of the present study was to determine base 
rates of low cognitive scores in healthy older adults on the 
CERAD-NAB using empirical data from an assessment 
of a large normative sample of healthy older participants. 
To account for the well-known influence of demographic 
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variables, we used standardized z-scores adjusted for age, 
gender, and education [25] in all analyses. The base rates 
of low scores in the normative sample were calculated for 
multiple cut-off scores for the entire battery. In a further 
step, we provide a summary figure that tabulates the num-
ber of low CERAD scores for six cut-off scores (i.e., 1st, 
2.5th, 7th, 10th, 16th, and 25th percentile) to aid clinicians 
to diagnose and differentiate between normal and abnor-
mal performance. To examine the usefulness of this sum-
mary figure in identifying individuals at risk for cognitive 
deterioration at a very early stage, baseline performance of 
initially healthy participants who developed AD dementia 
several years later was compared with participants who 
remained healthy.
Methods
Participants
The study sample consisted of 1,099 healthy older partici-
pants from the BASEL study (BAsel Study on the ELderly) 
aiming to investigate preclinical cognitive markers of AD 
(see [26, 27] for details) and who constituted the refer-
ence (i.e., the normative) sample for the German version 
of the CERAD-NAB [28]. Baseline testing was conducted 
between 1997 and 2001. A detailed description of the bi-
annual follow-up assessments within the BASEL study 
is described elsewhere [26]. Eighteen participants were 
excluded from the baseline sample because a detailed 
review of the charts at follow-up revealed that these individ-
uals should have been excluded based on medical exclusion 
criteria [i.e., prostate carcinoma (n = 5), use of psychoac-
tive substances (n = 3), loss of consciousness of more than 
5 min (n = 2), cardiac dysfunction/aortic stenosis (n = 2), 
sensory deficits (n = 2), history of high temperature epi-
sode (n = 2), temporal arteritis (n = 1), or chronic pain 
(n = 1)]. Thus, the final sample consisted of 1,081 Ger-
man-speaking healthy normal participants (407 women/674 
men). Age ranged from 49 to 92 years (M = 68.6 years; 
SD = 7.8 years), and participants had a mean educational 
level of 12.5 years (SD = 3.0 years; range 7–20 years). 
Mini-Mental State Examination (MMSE; [29]) test scores 
ranged from 24 to 30, with a mean of 28.9 (SD = 1.1). To 
ensure healthy baseline cognitive status of all participants, 
the following procedure to establish the gold standard was 
applied: All participants were interviewed with a compre-
hensive medical questionnaire and were only included in 
the analyses, when they were cognitively healthy. Partici-
pants were excluded if they fulfilled any of the following 
criteria (see also [27]): (1) severe hearing, visual, or verbal 
deficits that interfered with the administration of neuropsy-
chological testing; (2) severe motor deficits that interfered 
with everyday life; (3) severe systemic diseases (e.g., 
severe cardiac, renal, or liver dysfunctions, or severe endo-
crinological, or gastrointestinal diseases); (4) chronic pain; 
(5) major psychiatric disorders according to the fourth edi-
tion of the DSM (DSM-IV; [30]); (6) current use of psycho-
active substances; (7) current or past diseases of the central 
nervous system; (8) cerebrovascular diseases (e.g., stroke, 
transient ischemic attack); (9) generalized atherosclero-
sis; and (10) diseases or events during life that could have 
negatively affected the central nervous system (e.g., head 
trauma with loss of consciousness >5 min, alcohol abuse, 
or general anesthesia within the last 3 months). In addition, 
if a participant exhibited low cognitive performance (i.e., 
a z-score ≤ −1.96 in more than one of 11 CERAD-NAB 
variables, including the MMSE [29] (see [27] for details) 
and their spouses (or another family member) reported a 
decline of the participant’s cognitive functions, the partici-
pant was excluded from the normative sample.
Additionally, two subsamples of this normative sam-
ple were considered to examine potential differences in 
the number of low scores (see “Analyses” section) already 
at this stage of normalcy between participants who later 
developed AD dementia (NC–AD) and participants who 
remained cognitively healthy (NC–NC). Even a marginal 
difference in the number of low scores between these two 
samples would corroborate the importance to take base 
rates into account. The NC–NC subsample consisted of 26 
participants who remained healthy during the whole obser-
vation time and who were matched for age (±5 years), gen-
der (exact), and education (±5 years) to the 26 participants 
who were healthy at baseline, but developed AD dementia 
years later. In addition, each NC–NC participant needed 
to be in the study for at least as long as his/her NC–AD 
counterpart. AD was diagnosed by the Memory Clinic 
Basel according to the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzhei-
mer’s Disease-Related Disorders Association (NINCDS–
ADRDA) criteria [31] and the DSM-IV [30] after referral 
from study coordinators due to participant—or informant-
based concerns about cognitive deterioration or objec-
tive cognitive decline. Diagnosis was based on additional 
neuropsychological results, magnetic resonance imaging, 
medical and neurological examination as well as blood and 
serum analyses [32]. The two subgroups were comparable 
with respect to age, years of education, gender distribution, 
and MMSE score, but differed with respect to observa-
tion time such that NC–NC participants were significantly 
longer in the study compared to NC–AD participants (see 
Table 1). AD dementia was diagnosed in the NC–AD group 
after approximately 8 years (M = 8.5 years, range 3.2–
13.3 years). The study was approved by the Ethics Com-
mittee of both Basel (Switzerland) and was performed in 
accordance with the ethical standards laid down in the 1964 
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Declaration of Helsinki and its later amendments. All par-
ticipants gave written informed consent.
Neuropsychological measures
All participants were administered the German version of 
the CERAD-NAB [21, 22]. This battery included seven 
subtests measuring verbal episodic learning (Wordlist–
Encoding), verbal episodic memory (Wordlist–Delayed 
recall and Recognition), constructional praxis (Figures–
Copy), visual episodic memory (Figures–Delayed recall), 
executive functions (verbal fluency), and language (Boston 
Naming Test, 15-items). Additionally, we computed three 
variables: a measure reflecting the proportion of correct 
words recalled during verbal delayed recall relative to the 
words recalled at word list learning trial 3 (Wordlist–Sav-
ings), a measure representing the total number of intrusions 
at Wordlist–Encoding and Wordlist–Delayed recall (Word-
list–Intrusion errors), and a measure describing the propor-
tion of correctly reproduced figures at Figures–Delayed 
Recall relative to Figures–Copy (Figures–Savings). A 
description of these tests is provided in Table 2. Altogether, 
ten raw scores and demographically adjusted for age, gen-
der, and education z-scores were derived (see [25, 33]). 
Because education is a strong predictor for premorbid cog-
nitive performance, the number of years of education was 
used as its surrogate [13, 34, 35]. A summary of the overall 
neuropsychological CERAD-NAB test performance is pro-
vided in Table S1 in the electronic Supplementary Materi-
als (see Online Resource 1).
Analyses
Pearson product moment correlations were performed on 
the z-scores of all ten CERAD-NAB variables to illustrate 
subtest intercorrelations. The prevalence of CERAD-NAB 
low scores were calculated from the overall normative 
sample and both subsamples for six different cut-off scores 
that are frequently applied in clinical practice (see, e.g., 
[13]). The cut-off scores are listed below.
1. 1st percentile (z-score ≤ −2.32).
2. 2.5th percentile (z-score ≤ −1.96).
3. 7th percentile (z-score ≤ −1.48).
4. 10th percentile (z-score ≤ −1.28).
5. 16th percentile (z-score ≤ −1.00).
6. 25th percentile (z-score ≤ −0.67).
Because memory impairment alone is sufficient for a 
diagnosis of amnestic MCI [9], an additional analysis was 
conducted focusing only on the CERAD-NAB memory 
domains. Thus, the prevalence of low CERAD-NAB scores 
in the verbal and visual memory was calculated: Wordlist–
Encoding, Wordlist–Delayed recall, Wordlist–Discrimina-
bility, Wordlist–Savings, Wordlist–Intrusion errors, Fig-
ures–Delayed recall, and Figures–Savings. These results 
are reported in the electronic Supplementary Material sec-
tion (see Online Resource 2). To estimate the variability of 
the number of low scores in the 10 CERAD-NAB variables 
as well as to obtain the 95 % confidence intervals (CI), we 
computed 1,000 bootstrap replicates [36].
In order to aid clinicians in daily practice and to facili-
tate clinical decision making (i.e., to determine whether a 
certain cognitive profile should be considered as normal or 
impaired), we aimed to provide a summary figure with the 
exact percentages of healthy older participants who obtain 
a certain number of low scores at or below each of the cut-
off scores. Because cognitive impairment (due to any rea-
son) is variably defined in clinical practice, we determined 
that probable cognitive impairment may be assumed, when 
<10 % of healthy older adults obtain a certain number of 
low scores below a given cut-off score (see also [1, 12]). 
That is, if the number of scores below a certain cut-off score 
was obtained by approximately 10 % or less participants 
Table 1  Demographic characteristics and MMSE score of the two subsamples [i.e., the normal control group who remained healthy (NC–NC) 
and the initially healthy participants who progressed to AD dementia (NC–AD)]
a NC–NC = cognitively healthy participants who remained healthy
b NC–AD = initially healthy participants who progressed to Alzheimer’s disease dementia
c SD standard deviation
d χ2 test
e MMSE Mini-mental state examination [29]
NC–NCa (n = 26) NC–ADb (n = 26) T/χ2 p value
Age ± SDc (years) 72.3 ± 5.4 72.8 ± 4.6 0.33 0.74
Education ± SD (years) 12.8 ± 2.8 12.6 ± 2.7 −0.20 0.84
%women 42.3 42.3 0.00d 1.00
MMSEe ± SD 29.1 ± 1.0 28.7 ± 1.4 −1.15 0.26
Observation time ± SD (years) 10.8 ± 3.03 7.8 ± 2.7 −3.74 <0.001
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of the normative sample, we labeled this performance as 
probable cognitive impairment. Of course, any other cutoff 
(e.g., 5th percentile) could be used depending on the need 
of the examiner (e.g., high sensitivity vs. high specificity; 
the 10 % cutoff used here serves as an example).
To examine whether this critical 10 % border line may 
detect very early and subtle signs of cognitive impairment 
for each of the six cut-off scores, we compared baseline 
neuropsychological performance of 26 healthy participants 
who progressed to AD dementia (NC–AD) years later and 
their matched control group (NC–NC). Two-sided Fisher’s 
exact tests were performed to determine baseline differ-
ences (i.e., at a healthy stage) in the subgroups, using an 
alpha level of p < 0.05. All statistical analyses were per-
formed with SPSS version 21 (SPSS Inc. IBM company, 
2012).
Results
The correlation analysis between the z-scores of the ten 
CERAD-NAB tests revealed a pattern of coefficients 
that were mostly small to medium, indicating minimal 
to modest multicollinearity. Nearly all the correlations 
were smaller than 0.35. The largest correlations were 
as follows: Figures–Delayed Recall and Figures–Sav-
ings = 0.89, Wordlist–Delayed Recall and Wordlist–Sav-
ings = 0.76, Wordlist–Delayed Recall and Wordlist–
Encoding = 0.648, and Wordlist–Delayed Recall and 
Wordlist–Recognition = 0.47.
Figure 1 shows the cumulative percentages of healthy 
individuals who have a specific number of low test scores 
at or below each of the six cut-off scores. Because the 
percentage of participants who obtain seven or more low 
scores was very small (i.e., ≤7.5 %) even for the less strin-
gent cut-off scores, Fig. 1 only illustrates the percentage 
of participants who obtained up to six low scores (i.e., ≥1, 
≥2, ≥3, ≥4, ≥5, ≥6). These data show that a high percent-
age of the normative sample obtains at least one or more 
low scores at most cut-off scores and that the number of 
low scores varies as a function of the cut-off score.
In addition to the exact percentage of healthy individuals 
who obtain a certain number of low scores at or below each 
cut-off score, Fig. 2 provides information about the num-
ber of low scores required to determine probable cognitive 
impairment as well as the 95 % CI calculated by using the 
bootstrap method [36]. Given our definition, we set the crit-
ical border, where approximately 10 % of all participants 
obtain a certain number of low scores (see Fig. 2; white 
area). This 10 % border serves as a critical threshold to dif-
ferentiate between broadly normal numbers of low scores 
(see Fig. 2, light gray area) and an ambiguous area repre-
senting higher uncertainty about the diagnostic accuracy 
(see Fig. 2, dark gray area), i.e., participants whose number 
of low scores is situated in the light gray area are likely to 
be diagnosed as cognitively healthy, because a high per-
centage of the normative sample obtained a similar number 
of low scores, whereas the cognitive status of individuals 
whose number of low scores falls above the border in the 
dark gray area may be considered as abnormal, because 
only a small number (at most ≤7.5 % at 25th percentile, 
see Fig. 2 last column) of healthy older adults obtain such 
a high number of low scores. Thus, according to Fig. 2, 
when using the 10 % border as the critical threshold, prob-
able cognitive impairment across all 10 scores would be 
based on obtaining one or more low scores ≤1st percentile 
Table 2  Description of neuropsychological subtests of the CERAD-NABa [21, 22] used in this study
a CERAD-NAB Consortium to Establish a Registry for Alzheimer’s Disease-Neuropsychological Assessment Battery
b BNT Boston naming test
Test variable Test description Function
CERAD-NABa Wordlist–Encoding Total number of correctly learned words across three learning trials  
(number of words per trial = 10)
Verbal episodic learning
CERAD-NABa Wordlist–Delayed recall Total number of correctly remembered words after Wordlist–Encoding Verbal episodic memory
CERAD-NABa Wordlist–Savings Proportion correct words recalled during Wordlist–Delayed recall relative 
to words learned at Wordlist–Encoding learning trial 3
Verbal episodic memory
CERAD-NABa Wordlist–Discriminability Percent of correctly recognized words from Wordlist–Encoding Verbal episodic memory
CERAD-NABa Wordlist–Intrusion errors Total number of intrusions at Wordlist–Encoding and Wordlist–Delayed 
recall
Executive functions
CERAD-NABa Figures–Copy Copy of four figures (circle, diamond, overlapping rectangles, cube) Constructional praxis
CERAD-NABa Figures–Delayed recall Recall of figures reproduced at Figures–Copy Visual episodic memory
CERAD-NABa Figures–Savings Proportion correctly reproduced figures at Figures–Delayed recall relative 
to Figures–Copy
Visual episodic memory
Verbal fluency–Animals Number of animals reproduced within 1 min Executive functions
BNTb (15-items) Spontaneous naming of 15 black and white line drawings Language
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(z ≤ −2.32; obtained by 10.1 % of the normative sample), 
two or more low scores ≤2.5th percentile (z ≤ −1.96; 
obtained by 8.5 % of the normative sample), three or more 
low scores ≤7th percentile (z ≤ −1.48; obtained by 11.2 % 
of the normative sample), four or more low scores ≤10th 
percentile (z ≤ −1.28; obtained by 9.5 % of the norma-
tive sample), five or more low scores ≤16th percentile 
(z ≤ −1.00; obtained by 9.3 % of the normative sample), 
or six or more low scores ≤25th percentile (z ≤ −0.67; 
obtained by 11.9 % of the normative sample). The results 
of the separate analysis with the verbal and visual episodic 
memory domain only are reported in the electronic Supple-
mentary Material section (see Online Resource 2).
Figure 3 illustrates the percentage of the NC–NC and 
NC–AD groups situated in the critical area beneath the 
10 % border (see Fig. 2) for each cut-off score at baseline 
examination. Consistently, more NC–AD participants are 
situated in the critical dark gray area compared to NC–NC 
participants irrespective of the used cut-off score (see Fig. 3; 
Table 3). Two-sided Fisher’s exact tests were performed to 
examine potential baseline differences of the NC–NC and 
NC–AD groups. These results indicate only differences for 
less stringent cutoffs (i.e., 25th and 16th percentile) and a 
statistical trend toward differences in participants who later 
progressed to AD dementia to be located in the critical dark 
gray area compared to individuals who remained healthy, for 
the 10th percentile (see Table 3). It has to be noted that the 
OR for the 16th percentile could not be calculated because 
the denominator was zero. For purposes of estimation, we 
added the value 0.5 to each cell in the contingency table. The 
results of the separate analysis with the verbal and visual 
episodic memory domain only are reported in the electronic 
Supplementary Material section (see Online Resource 2). 
The final set of analyses compared a simultaneous appli-
cation of all impairment-criterion cut-off scores across 
groups. That is, we computed the base rate in the normative 
sample of meeting one or more criteria for probable cogni-
tive impairment across the ten scores when all six cut-off 
scores are applied simultaneously. In the entire normative 
sample, 22 % met criteria for cognitive impairment based 
on meeting one or more of the criteria in the white area in 
Fig. 2 (i.e., this is the percentage of people who meet crite-
rion when all criteria are considered). In the subsample of 26 
NC–NC participants, 19 % met any of the criteria, whereas 
Fig. 1  Cumulative percentages of healthy older participants with a particular minimum number of low scores in the CERAD-NAB for six dif-
ferent cut-off scores
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54 % of the 26 NC–AD participants met criteria for cogni-
tive impairment based on meeting one or more of the criteria 
of the criteria in the white area in Fig. 2. This difference is 
statistically significant [p = 0.02, OR = 4.9, 95 % CI (1.41, 
16.99)]. The same analysis was conducted for the memory 
domain only, and results are reported in the electronic Sup-
plementary Material section (see Online Resource 2). More-
over, in the electronic Supplementary Material section, we 
also provide additional variations of combined criteria and 
their corresponding base rates (see Online Resource 3).
Discussion
This study provides information about the base rates of low 
scores in the CERAD-NAB in a normative sample of older 
adults using six different cut-off scores commonly applied 
in clinical practice and research. The summary figure 
(Fig. 2) may be used as an important supplement in clinical 
practice when assessing cognitive performance and aims to 
reduce diagnostic errors in clinical decision making. Our 
main results support a number of studies demonstrating 
that a substantial percentage of healthy children [37–39], 
healthy adults [40, 41], and healthy older adults [1, 3, 5, 
15] will obtain scores that fall within abnormal ranges 
when multiple tests are administered.
According to the Gaussian distribution, the number of 
low scores varies as a function of the cut-off score—the 
higher the cut-off score, the more abnormal test scores 
are required to diagnose cognitive impairment. However, 
the use of a certain cut-off score critically relates to the 
sensitivity and specificity of a test. For example, using a 
Fig. 2  Base rates (in %) of demographically adjusted low z-scores 
out of ten CERAD-NAB variables (far left column) for six different 
cut-off scores (second row from the top). CI 95 % confidence inter-
val, cp cumulative percentage. The white area represents a criti-
cal border where circa 10 % of all participants (N = 1,081) obtain 
a certain number of low scores and serves a threshold to differenti-
ate between low (light gray area) and high (dark gray area) proba-
bilities of pathological performance. Thus, neuropsychological results 
located in the light gray area would be interpreted as within normal 
limits, whereas results in the dark gray area would be interpreted as 
probable cognitive impairment
414 Eur Arch Psychiatry Clin Neurosci (2015) 265:407–417
1 3
less stringent criterion for impairment [e.g., the 25th per-
centile (z-score ≤ −0.67)] indeed increases the identifi-
cation of true impairment (increased sensitivity), but it is 
also associated with reduced specificity (i.e., the percent-
age of healthy individuals erroneously being classified as 
impaired is high; see Fig. 1) [12]. Moreover, administer-
ing more than one neuropsychological test, which is man-
datory to obtain a comprehensive understanding of some-
one’s cognitive performance, yields multiple test scores 
and inherently increases the probability of abnormal scores 
[12, 14, 15]. For example, Schretlen et al. [15] reported 
that when examining healthy adults’ cognitive abilities 
by administering a test battery containing 10, 25 or 43 
subtests, 15, 40 and 57 %, respectively, of healthy adults 
obtain two or more scores below the 7th percentile (i.e., 
z-score = −1.5). Moreover, choosing a more stringent cri-
terion (z-score = −1.96), still 3, 13 and 24 %, respectively, 
obtain two or more low scores.
Beside these methodological issues, possible explana-
tions for low test performance among these healthy adults 
may be due to situational or personal factors such as 
motivational fluctuations, increased distractibility during 
Fig. 3  Percentage of normal controls who remained normal (NC–
NC; n = 26) and of initially healthy participants who later obtained 
a diagnosis of AD dementia (NC–AD; n = 26) situated in the critical 
dark gray area beneath the 10 % border (see Fig. 2) at each cutoff 
(x-axis) at baseline
Table 3  Comparison of percentages of participants (NC–NCa, NC–ADb) situated in the dark gray area in Fig. 2 (at baseline)
* p value < 0.05
a NC–NC = cognitively healthy participants who remained healthy
b NC–AD = initially healthy participants who progressed to Alzheimer’s disease dementia
c Dark gray area = to be considered as a pathological result (see Fig. 2)
d Fisher’s p value tested by Fisher’s exact test
e OR odds ratio
f CI confidence interval
% in the dark gray areac p valued ORe (95 % CIf)
NC–NCa (%) NC–ADb (%)
25th percentile 7.7 34.6 0.04* 6.35 (1.22, 33.19)
16th percentile 0 23.1 0.02* 16.8 (0.90, 315.89)
10th percentile 3.8 23.1 0.10 7.5 (0.83, 67.49)
7th percentile 11.5 23.1 0.47 2.3 (0.51, 10.41)
2.5th percentile 3.8 11.5 0.61 3.3 (0.32, 33.62)
1st percentile 3.8 15.4 0.35 4.6 (0.47, 43.78)
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testing, inattentiveness, and measurement error [20], or 
also longstanding personal weaknesses in certain areas or 
intraindividual cognitive variability across different cogni-
tive domains [5, 42]. Another explanation of low scores in 
cognitively normal adults is the possibility of poor effort. 
However, as Binder et al. [20] mention in their review—
and this is very much in line with our own observations—
participants taking part in research studies rarely exhibit 
insufficient effort, since their participation is voluntary. 
Moreover, systematic and random errors as additional 
sources for low scores were minimized as best as possi-
ble. Specifically, due to the large number of participants in 
this study, multiple examiners were needed to administer 
the tests. All examiners were thoroughly trained by expe-
rienced neuropsychologists, and instructions were given 
in a highly standardized way. In order to reduce any dis-
comfort of participants, a warming-up chat was carried-out 
at the beginning of the examination, which took place in a 
quiet room without distractors. In addition, if necessary and 
appropriate, short breaks during the testing were allowed to 
avoid fatigue. To safeguard against errors at data entry, this 
procedure was triple-checked. Thus, these results empha-
size that low scores do not necessarily need to be indicative 
of impairment, but may also represent normal variability of 
cognitive abilities within healthy adults. This is also sug-
gested by a number of recent studies which illustrate that 
a considerable percentage of participants (up to 25 %) 
are diagnosed as cognitively impaired at baseline evalua-
tion but revert to normal levels of functioning at follow-up 
examination [43–45], indicating diagnostic instability over 
time. Indeed, some of these misdiagnosed patients may 
have reverted due to adequate treatment of factors that may 
have caused cognitive impairment other than neurodegen-
eration (e.g., mood disorder, vascular risk factors). How-
ever, it can be assumed that this high number of individuals 
exhibiting improved or normal cognition at follow-up also 
contains a certain number of incorrectly diagnosed people 
at baseline because the probability of obtaining some low 
scores was not taken into account [44]. Interestingly, there 
is evidence that the likelihood to score within normal limits 
at follow-up is higher when the low scores at baseline were 
obtained in non-memory tests (i.e., non-amnestic MCI) 
[44, 45]. These results indicate that, in addition to the pure 
number of variables with a low score, it is important to also 
consider the affected cognitive domain.
The present study, however, also illustrates that some of 
these “healthy” participants may not be healthy and might 
be at a higher risk to progress to AD (i.e., they are in a 
prodromal stage of dementia). For example, our findings 
show that six or more scores (out of ten) below the 25th 
percentile occurred in about 12 % of the normative sample 
(see Fig. 2), in 8 % of the 26 older adults who remained 
cognitively healthy over time, but in almost 35 % of older 
adults who progressed to dementia (see Fig. 3). However, 
this result must be interpreted with caution because sample 
sizes were small. Nevertheless, the future dementia patients 
might have obtained low scores because they were already 
on the path of cognitive decline associated with future 
dementia. This thought corroborates with findings of cur-
rent neuropsychological research investigating the preclini-
cal stages of MCI and AD suggesting that low cognitive 
performance can be evidenced in a premorbid phase of later 
progressors to dementia more than a decade before diagno-
sis [7, 26, 46, 47]. For example, Amieva et al. [46] found in 
a sample of 350 preclinical AD patients and in demographi-
cally matched healthy controls that semantic and episodic 
memory declined 9–12 years prior to the diagnosis of AD 
dementia [46]. In light of these considerations, using our 
summary figure (Fig. 2) may help to improve diagnostic 
decision making in clinical practice. An illustrative exam-
ple for the application of these base rates can be found in 
the electronic Supplementary Materials section (see Online 
Resource 4).
This study has some limitations to consider. The sample 
used in this study was a convenience sample of a subsam-
ple of the original Basel study initiated in 1959, consisting 
predominantly of (former) employees of the pharmaceu-
tical industry in Basel [48]. Thus, its representativeness 
is somewhat limited to rather better educated older indi-
viduals. Additionally, all CERAD-NAB variables exhibit a 
skewed distribution, comparable to most neuropsychologi-
cal test variables. However, a close approximation to a nor-
mal distribution for all neuropsychological variables was 
accomplished by applying monotone transformations [25]. 
Because we aimed to improve diagnostic accuracy in a neu-
ropsychological assessment and low cognitive performance 
is indicative of impairment, normally distributed scores 
are primarily needed for the diagnostically relevant lower 
tail, while a more liberal criterion for the upper tail does 
not influence diagnostic validity. Further, although all par-
ticipants underwent a careful and comprehensive neuropsy-
chological and medical screening, it is not known whether 
some of the participants in the normative study were in a 
prodromal stage of AD, a condition that would mitigate 
the results. As illustrated in the subsample of 26 partici-
pants who later were diagnosed with dementia, we presume 
that some actually might have already been in a prodromal 
stage. The results from the baseline comparison between 
the NC–NC and NC–AD group are based on a very small 
sample and rather serve as a qualitative comparison. These 
results need to be studied in a larger sample. Moreover, we 
treated all CERAD-NAB variables as equally informative, 
although a high number of them were related to episodic 
memory.
Early and accurate diagnosis of MCI and AD represents 
a major and challenging goal of current neuropsychological 
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research. The results of the present study substantially con-
tribute to an improvement and facilitation of neuropsycho-
logical diagnostics and are highly relevant in clinical prac-
tice by illustrating that awareness of the base rates of low 
scores has important implications for the diagnosis of MCI 
or prodromal AD. It is important to note that these base 
rate data are meant to only supplement clinical judgment, 
as neuropsychological test results need to be interpreted in 
conjunction with results of additional examinations (e.g., 
the patient’s medical history and premorbid functioning 
(see also [19], informant-based and self-reported changes 
in the activities of daily living, structural magnetic reso-
nance imaging, results cerebrospinal fluid analyses [49], 
etc.). Future research should investigate whether base rates 
of low scores in specific cognitive domains may have dif-
ferential diagnostic and prognostic value. Additionally, as 
already mentioned, a broad range of cut-off scores is used 
to assess cognitive impairment. Future investigations with a 
large longitudinal sample might help to empirically define 
the optimal cut-off score(s) to discriminate between incipi-
ent neurocognitive disorder and normal aging. Moreover, 
because repeated neuropsychological testing is commonly 
used to evaluate decline over time, future research may 
apply the same methodology to determine the base rates of 
abnormal change of scores. By defining normal variability 
in change scores at subsequent evaluations, interpretation 
of follow-up results will be more valid.
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